RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:CD8+ TiLs and T-cell exhaustionUnlike atezolizumab, pela’s clinical activity was lost when combined with avelumab, a PD-LI inhibitor with a native Fc region that is capable of binding Fc receptors and inducing ADCC. The addition of avelumab eliminated pre-existing TIL expansion in the blood highlighting the importance of TIL expansion following pela therapy.
The same elimination of pre-existing TILs and TILs expansion in the blood does not happen when ONCY's pelareorep is combined with other ICIs. Instead the addition of pelareorep results in the remodeling of an mmunosuppressive TME and the the priming of the immune systems.
The result is TME - T-cell expansion that prepares the TME for the synergistic addition of ICI's like atezolizumab and pembrolizumab, and other Fc de-activated ICIs, other than those like Bavencio (avelumab).